There are multiple studies on the association of CD133 expression with poor prognosis in colorectal cancer (18), pancreatic cancer, hepatocellular carcinoma (19), neuroblastoma (20), and in patients with glioma (21). This evidence concerns the gene PROM1 and glioma.